These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 38349726)

  • 1. Molecular mechanisms in MASLD/MASH-related HCC.
    Wang X; Zhang L; Dong B
    Hepatology; 2024 Feb; ():. PubMed ID: 38349726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases.
    Sandireddy R; Sakthivel S; Gupta P; Behari J; Tripathi M; Singh BK
    Front Cell Dev Biol; 2024; 12():1433857. PubMed ID: 39086662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histidine-rich glycoprotein in metabolic dysfunction-associated steatohepatitis-related disease progression and liver carcinogenesis.
    Foglia B; Sutti S; Cannito S; Rosso C; Maggiora M; Casalino A; Bocca C; Novo E; Protopapa F; Ramavath NN; Provera A; Gambella A; Bugianesi E; Tacke F; Albano E; Parola M
    Front Immunol; 2024; 15():1342404. PubMed ID: 38469298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment.
    Llovet JM; Willoughby CE; Singal AG; Greten TF; Heikenwälder M; El-Serag HB; Finn RS; Friedman SL
    Nat Rev Gastroenterol Hepatol; 2023 Aug; 20(8):487-503. PubMed ID: 36932227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD): Executive Summary.
    ; ;
    Diabetologia; 2024 Jun; ():. PubMed ID: 38869512
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
    ; ;
    Obes Facts; 2024; 17(4):374-444. PubMed ID: 38852583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Τ cell-mediated adaptive immunity in the transition from metabolic dysfunction-associated steatohepatitis to hepatocellular carcinoma.
    Papadopoulos G; Giannousi E; Avdi AP; Velliou RI; Nikolakopoulou P; Chatzigeorgiou A
    Front Cell Dev Biol; 2024; 12():1343806. PubMed ID: 38774646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MASLD-Related HCC-Update on Pathogenesis and Current Treatment Options.
    Leyh C; Coombes JD; Schmidt HH; Canbay A; Manka PP; Best J
    J Pers Med; 2024 Mar; 14(4):. PubMed ID: 38672997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathology and Pathogenesis of Metabolic Dysfunction-Associated Steatotic Liver Disease-Associated Hepatic Tumors.
    Takahashi Y; Dungubat E; Kusano H; Fukusato T
    Biomedicines; 2023 Oct; 11(10):. PubMed ID: 37893134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD).
    ; ; ;
    J Hepatol; 2024 Sep; 81(3):492-542. PubMed ID: 38851997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incretin-based investigational therapies for the treatment of MASLD/MASH.
    Brouwers B; Rao G; Tang Y; Rodríguez Á; Glass LC; Hartman ML
    Diabetes Res Clin Pract; 2024 May; 211():111675. PubMed ID: 38636848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NAFLD (MASLD)/NASH (MASH): Does It Bother to Label at All? A Comprehensive Narrative Review.
    Sergi CM
    Int J Mol Sci; 2024 Aug; 25(15):. PubMed ID: 39126031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sex-based differences in natural killer T cell-mediated protection against diet-induced steatohepatitis in Balb/c mice.
    Cuño-Gómiz C; de Gregorio E; Tutusaus A; Rider P; Andrés-Sánchez N; Colell A; Morales A; Marí M
    Biol Sex Differ; 2023 Nov; 14(1):85. PubMed ID: 37964320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Time-Restricted Feeding Attenuates Metabolic Dysfunction-Associated Steatohepatitis and Hepatocellular Carcinoma in Obese Male Mice.
    Das M; Kumar D; Sauceda C; Oberg A; Ellies LG; Zeng L; Jih LJ; Newton IG; Webster NJG
    Cancers (Basel); 2024 Apr; 16(8):. PubMed ID: 38672595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Lasting Effects of COVID-19 on the Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
    Backer S; Khanna D
    Cureus; 2023 Sep; 15(9):e45231. PubMed ID: 37842470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Probiotic Mixture Ameliorates a Diet-Induced MASLD/MASH Murine Model through the Regulation of Hepatic Lipid Metabolism and the Gut Microbiome.
    Zhang F; Lo EKK; Chen J; Wang K; Felicianna ; Ismaiah MJ; Leung HKM; Zhao D; Lee JC; El-Nezami H
    J Agric Food Chem; 2024 Apr; 72(15):8536-8549. PubMed ID: 38575146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulatory T cell: a double-edged sword from metabolic-dysfunction-associated steatohepatitis to hepatocellular carcinoma.
    Wang H; Tsung A; Mishra L; Huang H
    EBioMedicine; 2024 Mar; 101():105031. PubMed ID: 38401419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic management of metabolic dysfunction associated steatotic liver disease.
    Zeng J; Fan JG; Francque SM
    United European Gastroenterol J; 2024 Mar; 12(2):177-186. PubMed ID: 38193865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. From MASH to HCC: the role of Gas6/TAM receptors.
    Apostolo D; Ferreira LL; Vincenzi F; Vercellino N; Minisini R; Latini F; Ferrari B; Burlone ME; Pirisi M; Bellan M
    Front Immunol; 2024; 15():1332818. PubMed ID: 38298195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FibroScan-aspartate transaminase: A superior non-invasive model for diagnosing high-risk metabolic dysfunction-associated steatohepatitis.
    Yin JY; Yang TY; Yang BQ; Hou CX; Li JN; Li Y; Wang Q
    World J Gastroenterol; 2024 May; 30(18):2440-2453. PubMed ID: 38764767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.